title: TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis.
abstract: Clonal responses of Mycobacterium tuberculosis-specific CD4(+) or CD8(+) T effector cells producing antituberculosis cytokine IFN-γ in the context of immune protection against tuberculosis remain poorly characterized in humans. Utilizing decade-long TCR expertise, we previously developed a useful method to isolate clonotypic TCR sequences from Ag-specific IFN-γ-producing T cells and to specifically measure clonotypic TCR frequencies in the T cell pool. In this study, we investigated TCR Vβ repertoires/CDR3 usage, clonal expansion or dominance, and pulmonary trafficking or accumulation for purified protein deritative (PPD)-specific T effector cells producing IFN-γ during bacillus Calmette-Guérin (BCG) vaccination and subsequent M. tuberculosis challenge of macaques. We found that while PPD-specific CD4(+) and CD8(+) T effector clones employed diverse TCR Vβ repertoires, 30-33% of IFN-γ(+)CD4(+) T cell clones from three M. tuberculosis-infected macaques expressed TCR bearing a conserved residue leucine in CDR3. Many Ag-specific IFN-γ(+) CD4(+) and few CD8(+) T effector cells emerged as dominant clones during mycobacterial infections and underwent major recall expansion after pulmonary M. tuberculosis infection of BCG-vaccinated macaques. PPD-specific T cell clones readily trafficked to the airway or lung after BCG vaccination or M. tuberculosis infection, and some of them continuously accumulated in lungs during M. tuberculosis infection even after they became undetectable in the circulation. Importantly, remarkable recall expansion and pulmonary accumulation of T effector cells coincided with BCG-induced protection against tuberculosis. Thus, rapid clonal expansion and pulmonary accumulation of Ag-specific T effector cells appear to be one of the immune mechanisms underlying immunity against tuberculosis.
authors.affiliation: Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, IL 60612, USA.
authors.forename: George
authors.initials: G
authors.lastname: Du
authors.forename: Crystal Y
authors.initials: CY
authors.lastname: Chen
authors.forename: Yun
authors.initials: Y
authors.lastname: Shen
authors.forename: Liyou
authors.initials: L
authors.lastname: Qiu
authors.forename: Dan
authors.initials: D
authors.lastname: Huang
authors.forename: Richard
authors.initials: R
authors.lastname: Wang
authors.forename: Zheng W
authors.initials: ZW
authors.lastname: Chen
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002469:Cell Separation; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D005434:Flow Cytometry; D019672:Genes, T-Cell Receptor; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D009169:Mycobacterium tuberculosis / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014397:Tuberculosis, Pulmonary / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control
chemical_list: D001500:BCG Vaccine; D011948:Receptors, Antigen, T-Cell
references.citation: Tuberculosis (Edinb). 2003;83(1-3):98-106
references.pmid: 12758197
references.citation: Nat Rev Immunol. 2001 Oct;1(1):20-30
references.pmid: 11905811
references.citation: J Virol. 2004 Dec;78(24):14023-32
references.pmid: 15564509
references.citation: Curr Opin Microbiol. 2004 Feb;7(1):58-61
references.pmid: 15036141
references.citation: Infect Immun. 1995 Apr;63(4):1235-40
references.pmid: 7890378
references.citation: Immunol Rev. 2008 Dec;226:191-204
references.pmid: 19161425
references.citation: J Immunol. 2007 Jul 15;179(2):1331-9
references.pmid: 17617626
references.citation: J Infect Dis. 1990 Jul;162(1):8-12
references.pmid: 1972384
references.citation: Clin Exp Immunol. 2003 Aug;133(2):182-92
references.pmid: 12869023
references.citation: J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107
references.pmid: 17624830
references.citation: Lancet. 1993 Jul 17;342(8864):143-6
references.pmid: 8101257
references.citation: J Immunol Methods. 2006 Jan 20;308(1-2):19-35
references.pmid: 16403511
references.citation: PLoS One. 2009 Sep 04;4(9):e6905
references.pmid: 19730727
references.citation: Infect Immun. 2008 Jan;76(1):426-36
references.pmid: 17923514
references.citation: J Immunol. 2001 Apr 1;166(7):4525-33
references.pmid: 11254709
references.citation: PLoS Pathog. 2009 Apr;5(4):e1000392
references.pmid: 19381260
references.citation: Infect Immun. 2002 Feb;70(2):869-77
references.pmid: 11796622
references.citation: J Immunol. 2007 Dec 15;179(12):8287-96
references.pmid: 18056373
references.citation: J Immunol. 2005 Feb 15;174(4):2174-84
references.pmid: 15699149
references.citation: PLoS Pathog. 2010 Feb 26;6(2):e1000789
references.pmid: 20195465
references.citation: J Exp Med. 1993 Dec 1;178(6):2249-54
references.pmid: 7504064
references.citation: Science. 2002 Mar 22;295(5563):2255-8
references.pmid: 11910108
references.citation: J Immunol. 1996 Feb 15;156(4):1469-75
references.pmid: 8568249
references.citation: J Immunol. 1999 Feb 15;162(4):2204-16
references.pmid: 9973496
references.citation: Blood. 2003 Apr 1;101(7):2521-8
references.pmid: 12468436
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Virol. 2001 Sep;75(18):8690-6
references.pmid: 11507214
references.citation: Appl Environ Microbiol. 2002 Mar;68(3):1351-7
references.pmid: 11872487
references.citation: J Exp Med. 1995 Jul 1;182(1):21-31
references.pmid: 7540651
references.citation: Am Rev Respir Dis. 1993 Nov;148(5):1292-7
references.pmid: 7902049